Optimizing Medical Cannabis for You

Cannformatics Starts with You

We measure how your body responds to cannabis. Then we give you a recommendation for the strain/product and strength/dose that are most effective for your wellness goals. As your needs and goals change, you can always send a new sample to update your recommendations.

Our proprietary technology, is unique in its ability to detect and quantify biomarkers, found in human saliva, that indicate effective response to cannabis treatment. For the first time ever, medical cannabis users will know if the quantity, product/strain they are using is the most efficacious for the condition they are seeking to manage.

We are building the world’s first bioinformatics database dedicated to improving the knowledge and understanding of the relationship between an individual’s biology and the many complexities of the cannabis plant.

In the future, we will be collecting anonymous saliva samples to build the database, early participants will be contributing to improving medical cannabis science and will have the opportunity to be some of the first people to receive insights as the recommendation engine comes online. If you’re interested in being a Cannformatics early participant, please provide us with the information you are comfortable sharing.

To sign up for the private beta just answer these 3 questions (less than a minute).


Partnership Opportunities

We are partnering with medical providers, cannabis product companies, patient communities and medical cannabis researchers.


Investment Opportunities

We are currently seeking funding.



For all other inquiries.



Our Team has scientists with decades of combined experience and over 120 published scientific papers and patents in genetics, omics-based technology, bioinformatics, and computational biology & chemistry, working with leading IP protection and cannabis industry marketing talent.

Itzhak Kurek

- CEO and Co-Founder

Click For Background

Dr. Kurek is a senior biotech leader with experience in managing, consulting and research roles in the Ag-Biotech, Human and Nutritional Supplements, Renewable Energy and Biobased Products businesses. Dr. Kurek joined Cannformatics from Solix Algredients, a B2B supplier of algae-based natural ingredients where he served as R&D consultant at the Vice-President level. Previously, Dr. Kurek worked at Kiverdi inc., a company making high-value oils and chemicals from waste carbon sources, as the Senior Director of R&D. Dr. Kurek held research scientist positions at Pioneer Hi-Bred (DuPont), Verdia Inc. and Maxygen Inc. Dr. Kurek has published 20 peer reviewed scientific papers and 10 granted US and international patents cited over 1,800 times.

Dr. Kurek received his Ph.D. in Plant Sciences from Tel Aviv University and completed his postdoctoral research at the University of California, Davis. Dr. Kurek has also conducted research at the Technical University of Munich, John Innes Center Norwich, C.N.R.S Bordeaux and the Lawrence Berkeley National Laboratories.

Read Dr. Kurek's recent articles on cannabis and the Cannformatics approach:

How cannabinoids work part 1: Paths into the body

How cannabinoids work part 2: Paths through the body

How cannabinoids work part 3: Metabolism and elimination

Dr. Kurek's recent article on the role of cannabinoids in the plant:

Better Living through Biochemistry: The Molecules Cannabis Plants Make to Stay Vital

Robert McKee

- CTO and Co-Founder

Click For Background

Mr. McKee is a patent lawyer with expertise in genetics, machine learning/artificial intelligence, data privacy law and technology commercialization. Mr. McKee joined Cannformatics from his law practice where he writes patents and ensures compliance with data privacy laws, and develops IP protection strategies for very early stage companies to ensure value creation. Previously, Mr. McKee worked at Kiverdi Inc., a company making high-value oils and chemicals from waste carbon sources, as IP and Business Development Associate. Mr. McKee held a microbiologist position at the Texas Department of State Health Services.

Mr. McKee received his Master of Science in Technology Commercialization from the Red McCombs School of Business at the University of Texas, Austin. He holds a JD from the University of Houston, Texas and a BS in Microbiology from The University of Texas, Austin. Mr. McKee has also completed the UDACITY Machine Learning Engineer Nanodegree.

Mike Siani-Roses

- VP Computational Chemistry

Click For Background

Mr. Siani-rose has 20+ years of experience in regenerative medicine, biotechnology and bioinformatics. At Cannformatics, he provides project leadership for strategic corporate partnerships and leadership on computational biology and computational chemistry. He has been a project management consultant to Big Pharma/Biotech, directing projects that reach broadly across manufacturing organizations. Previously, as President and Founder of Theregen he raised $10M and led the company from preclinical through IND and two Phase I clinical trials for the implantable Anginera epicardial patch. He has extensive expertise in computational chemistry, drug discovery and bioinformatics from positions at Chiron Corporation (now Novartis), Kosan Biosciences and Affymetrix.

Mike has 45+ publications, and ten issued patents in drug discovery, laboratory automation, bioinformatics, and regenerative medicine. He received his BS in Chemical Engineering from the University of Rochester, did graduate work in Computer Science at UCSD, and attended the BioExecutive Institute in the Haas School of Business at UC Berkeley.

Ken Epstein

- VP Marketing

Click For Background

Mr. Epstein was a founding partner and brand strategist at WYD, a full service marketing agency specializing in all facets of the cannabis industry. Prior to joining WYD Ken was responsible for increasing revenue and brand equity for some of the world’s most powerful brands including; Clorox, Levi’s, Intel, Electronic Arts and Sunrun. At Sunrun Ken led the Brand and Corporate Communications team during Sunrun’s IPO raising over $251M in equity and led the brand launch of Brightbox Sunrun’s industry leading solar energy storage solution. He has extensive expertise in public relations, social media, and advertising.

Ken has a variety of marketing awards for TV, Billboard and Social Media campaigns including Emmy nominations, Webbys, One Show, and many more. He received his BA in Information and Communication Studies with a minor in Human Biology and Health Science from CSU, Chico. He is on the Board of Directors for Access Institute a San Francisco based non-profit provider of mental health services and Post-Doctoral Fellowship training.

Read Mr. Epstein’s article on exhibiting at a cannabis trade show


Dr. Donald Abrams

- Medical and Scientific Advisor

Click For Background

Donald I. Abrams, MD. is an oncologist at Zuckerberg San Francisco General and a Professor of Clinical Medicine at the University of California San Francisco. He has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. He received an A.B. in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977. After completing an Internal Medicine residency at the Kaiser Foundation Hospital in San Francisco, he became a fellow in Hematology/Oncology at the Cancer Research Institute of the University of California, San Francisco in 1980. He was one of the original clinician/investigators to recognize and define many early AIDS-related conditions. He has long been interested in clinical trials of complementary and alternative medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997 he received funding from the National Institute on Drug Abuse to conduct clinical trials of the short-term safety of cannabinoids in HIV infection. Subsequently he was granted funds by the University of California Center for Medicinal Cannabis Research to continue studies of the effectiveness of cannabis in a number of clinical conditions. He completed a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal uses. His last NIDA-funded trial investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain. His last study was an NIH-funded trial investigating vaporized cannabis in patients with Sickle Cell disease. He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website. He was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017.

Dr. Abram’s publications on Cannabis in Integrative Cancer Care:

Integrating cannabis into clinical cancer care

Using Medical Cannabis in an Oncology Practice

Cannabis in Cancer Care

Cannabis and Cancer: Decoding the connection

WATCH Dr. Abram’s video on Cannabis in Integrative Cancer Care

Tamar Maritz, MBA

- California Cannabis Market Advisor

Click For Background

Tamar Maritz is the current Director of Business Development at BDS Analytics, the leading market research and insights firm in the cannabis industry. With a strong background in market research and analytics consulting for some of the biggest fortune 500 tech companies, Tamar brings years of analytical and insight-driven experience to the cannabis industry, already having helped countless existing and up-and-coming operators thrive in the cannabis supply chain over the past 2.5 years. Coupled with an undergraduate degree in Biochemistry (followed by a research stint at the Weizmann Institute of Science in Israel) and an MBA with a focus on quantitative marketing strategy, she is able to provide a unique perspective and understanding of the industry from both the commercial and pharmaceutical ends.

WATCH BDS Analytics webinar presented by Mrs. Maritz’s on Breaking Down Year 1 of California Adult-Use Sales